Pill Identifier App

ISCAR MALI [Viscum album Tr. (P-LAF)] (Weleda)
ISCAR QUERCUS
[Viscum album Tr. (P-LAF)]

ISCAR MALI SPECIAL 25mg
[Viscum album Tr. (P-LAF)]

ISCAR QUERCUS SPECIAL 25mg
[Viscum album Tr. (P-LAF)]

Rx ONLY

Description

ISCAR MALI, ISCAR QUERCUS, ISCAR MALI SPECIAL 25mg and ISCAR QUERCUS SPECIAL 25mg are all made from Viscum album Tr. (P-LAF). They are homeopathic, sterile injectables for subcutaneous use.

Active ingredient:   Viscum album Tr. (P-LAF). Prepared according to the HPUS Class P aqueous fermentation method--1 part by weight of fresh plant material in five parts by weight of tincture. The quantity of tincture in each ampule is indicated in the section "How Supplied." Viscum album is a semi-parasitic plant that grows on different host trees. The species of the host tree is indicated by Mali = Apple tree and Quercus = Oak tree.

Inactive ingredients:   Water for injection, sodium chloride for isotonicity.

PHARMACOLOGIC CATEGORY

Homeopathic.

INDICATIONS

All ISCAR preparations are indicated as homeopathic medications for adjunct treatment of cancerous conditions, apathy, sadness, constipation and internal thermo-regulation problems. 1 Clinical experience shows that ISCAR MALI is primarily utilized in female patients and ISCAR QUERCUS in male patients. 6

Contraindications

  • Tuberculosis
  • Hyperthyroidism with unbalanced metabolic functions
  • Known allergy to mistletoe

Precautions

  • Hypersensitivity to mistletoe preparations: In these cases, desensitization must precede therapy .
  • Acute inflammatory condition or fever over 38 °C / 100.4 °F (distinct from genuine tumor-related pyrexia): Treatment should be stopped until the symptoms have disappeared .
  • Primary intracranial and intraspinal tumors or intracranial metastases: There is a potential risk of increasing intracranial pressure by administering ISCAR parenterally. Caution is indicated; if necessary, give ISCAR by mouth.
  • Pregnancy: While there is no evidence contraindicating its use, there is always concern using any drug during pregnancy. Therefore, exercise caution before using ISCAR.
  • Nursing mothers: It is not known whether this drug is distributed into breast milk. Because many drugs are distributed into breast milk, caution should be exercised when ISCAR is administered to a nursing mother.
  • Pediatric use: When children and infants are treated with ISCAR, a stronger reaction can be expected. Dosages should be increased more slowly and, as a rule, should not exceed a maximum dose of 50mg per day.
  • ISCAR MALI SPECIAL and QUERCUS SPECIAL should not be mixed with other injectable medications in the same syringe.

INTERACTIONS

All ISCAR preparations can be used during chemotherapy, hormone or radiation therapy; interactions with other drugs are unknown.

There has been no research on interactions with immune modulating drugs (i.e. Thymus extract). Concurrent use of such preparations with ISCAR or with ISCAR SPECIAL requires careful dosing; frequent monitoring of immune function parameters is recommended.

Adverse Reactions

Information is available on mistletoe preparations similar to ISCAR or ISCAR SPECIAL. These findings can be summarized as follows:

  • According to the report of the Canadian Breast Cancer Research Initiative, administration of mistletoe preparations can cause headache and/or chills as adverse effects. 2
  • Clinical studies state that these mistletoe preparations are well tolerated. 3,4,5 Inflammatory conditions such as gingivitis, flu-like symptoms and chills were found both in HIV-positive and healthy individuals, in one study performed on a small number of subjects. 3

Dosage and Administration

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Treatment with ISCAR MALI SPECIAL 25mg and ISCAR QUERCUS SPECIAL 25mg is administered in two distinct phases:

Induction Phase

Start with 1 box of Series 0 . Beginning with the 0.05mg tincture/ml ampule inject 3 times weekly, increasing the strength sequentially. Repeat with a second box of Series 0. If well tolerated by the patient, treatment can be instituted with ISCAR MALI SPECIAL 25mg or ISCAR QUERCUS SPECIAL 25mg.

Maintenance Phase:

The maintenance phase has been reached with the switch to ISCAR MALI SPECIAL 25mg or ISCAR QUERCUS SPECIAL 25mg, which is injected 3 times weekly subcutaneously. Progress should be monitored on a regular basis. With marked local reactions (more than 2"/5cm in diameter) and/or temperature reactions above 100.4 °F (38 °C), treatment should be stopped until the symptoms have subsided. Afterwards, treatment is resumed with a lower dose of ISCAR SPECIAL. This may be done by reducing the frequency of injection or by using a fraction of an ampule.

During the first year of treatment with ISCAR SPECIAL, it is recommended to continue treatment without injec-tion-free intervals. After the first year of treatment, the physician may recommend a 1-week injection-free interval following every sequence of 14 injections if progress is satisfactory.

Individual Reaction:   This may be recognized by at least one of the following:

  • Objective and subjective improvement in general condition-- including improved appetite and weight gain, better sleep, reduction in pain, patient feeling less tired, lightening of depressive mood and stimulation of eliminatory processes.
  • Improvement in immunological status-- normal leukocyte and/or lymphocyte counts are desirable. Eosinophilia with absence of allergic symptomatology is commonly seen. Immunological tests can help in establishing optimum dosage.
  • Temperature reaction-- these may vary, and include:
    1. Temperature rises once, a few hours after the injection;
    2. Re-establishment of physiological difference between morning and evening temperatures of at least 0.9 °F (0.5 °C);
    3. Rise in mean diurnal temperature.
  • Local inflammatory reaction-- reddening around the injection site to a maximum of 2" (5 cm) in diameter.

Frequency of Injections and Treatment Intervals:

All types of ISCAR are usually administered 3 times weekly. The best time tends to be in the mornings, or when the body temperature naturally rises.

After one year of treatment, if progress is satisfactory, the physician may recommend a 1-week injection-free interval following every sequence of 14 injections.

Important:     Although the above recommendations reflect common practice, the physician may recommend different dosage frequencies.

Method of Injection:

Injections of the contents of a 1-ml ampule of all types of should be given sub-cutaneously. ISCAR works systemically, so injections are often given in the abdominal region or thigh. Some researchers believe that there may be a local effect as well, so the physician may recommend administering the injection in the vicinity of the tumor. Irradiated areas and inflamed skin areas should be avoided. The distance from the tumor should be 1.2"-1.6" (3-4 cm).

How Supplied

Each package contains 7 × 1-ml ampules. When ordering, please be sure to specify the "host" type and strength desired.

STORAGE

Store at controlled room temperature (15-30 °C / 60-85 °F) away from direct sunlight, except for the "Special" which should be stored in the refrigerator (4-8 °C / 39-46 °F). To avoid local irritation, hold the ampule in your hand briefly to warm up the liquid before injecting.

STRENGTH
HOST TREE
Iscar (viscum album Tr. P-LAF)
MALI NDC QUERCUS NDC
Series 0 [0.05 mg (2 amp.), 0.5 mg (2 amp.), 5 mg (3 amp.)]
55946-500 -95 55946-508 -95
Special (25 mg)
55946-536 -95 55946-537 -95

References

  1. Julian, O. A., Materia Medica of New Homeopathic Remedies (Beaconsfield Publishers Ltd., Beaconsfield, Bucks., U.K., 1979), 556-562.
  2. Canadian Breast Cancer Research Initiative: Iscador: An Information Package. CBCRI, 1996, Toronto, Canada.
  3. Madelon van Wely, Matthias Stoss and Robert W. Gorter: Toxicity of a Standardized Mistletoe Extract in Immunocompromised and Healthy Individuals (American Journal of Therapeutics, Vol. 6, No. 1, 1999).
  4. R. W. Gorter, J. Stein, M. Stoss, M. Linder: Prospective, Longitudinal, Dose-Escalating, Randomized Phase I/II Study with Viscum album QuFrF and Iscador Qu Spezial in HIV Positives, Cancer Patients and Healthy, Non-Smoking Individuals (Forschende Komplementärmedizin, Vol. 3, No. 4, Aug 1996).
  5. E.M. Lukyanova, V.P. Chernyshov, L.I. Omelchenko, I.I. Slukvin, T.V. Pochinok, J.G. Antipkin, I.V. Voichenko, P. Heusser, G. Schniedermann: Viscum album (Iscador) Treatment of Immunocompromised Children after the Chernobyl Accident: Clinical and Immunological Investigations (Forschende Komplementärmedizin, Vol. 1, No. 2, Feb 1994).
  6. ISCAR in the Treatment of Malignant Conditions (Guidelines 2002, Weleda, Inc., Congers, NY 10920).

RELATED SOURCES OF INFORMATION

  • R. Grossarth-Maticek, H. Kiene, S. Baumgartner, R. Ziegler: Use of Iscador, an Extract of European Mistletoe (Viscum album), in Cancer Treatment: Prospective Nonrandomized and Randomized Matched-Pair Studies Nested within a Cohort Study (Alternative Therapies in Health and Medicine, May/June 2001, Vol. 7, No. 3).
  • Christine Murphy (Ed.): ISCADOR / Mistletoe in Cancer Therapy (2001, Lantern Books, New York, NY 10003).
  • Hans-Richard Heiligtag (Ed.): Anthroposophical Medicine and Therapies for Cancer (Mercury Press, Spring Valley, NY 10977).
  • ISCADOR--Compendium of Research Papers, 1986 (Mercury Press, Spring Valley, NY 10977).
  • ISCADOR--Compendium of Research Papers, 1986-1988 (Mercury Press, Spring Valley, NY 10977).
  • ISCADOR--Compendium of Research Papers, 1989-1991 (Mercury Press, Spring Valley, NY 10977).
  • ISCADOR--Compendium of Research Papers, 1990-1994 (Mercury Press, Spring Valley, NY 10977).

01-090102

Distributed by: Weleda, Inc., Congers, NY 10920

Hide
(web5)